Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Disorder

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07487155

Acronym

JUSTICE-TDAH

Enrollment

Registered

2026-03-23

Start date

2026-06-01

Completion date

2027-12-01

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Disorder With Hyperactivity (ADHD), Substance Use Disorder (SUD)

Brief summary

Substance use disorders (SUD) and attention deficit disorder with or without hyperactivity (ADHD) are frequently co-morbid, particularly among people under court supervision. The coexistence of these disorders increases the social and legal vulnerability of individuals. Better identification of ADHD in vulnerable people with SUD is essential to improving their care. This project aims to provide appropriate support for this at-risk population.

Interventions

OTHERWorkshop

Assess the 5 workshops, co-constructed by the scientific committee and thanks to feedback from the qualitative study

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult, under the supervision of the justice system or monitored by a correctional facility * Diagnosis of Substance Use Disorder (SUD) * Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) * No objection from the patient * Affiliated with a Social Security system

Exclusion criteria

* Severe or decompensated psychiatric disorders * Severe cognitive impairment * Lack of understanding of the French language * Refusal to participate

Design outcomes

Primary

Measure	Time frame	Description
80% of patients participated in the workshops	From enrollment to the end of wordshop at 6 months	The primary outcome measure is the acceptability of the program to participants in the pilot workshops, gathered through: * Semi-structured pre- and post-intervention interviews * A Likert scale * Workshop participation rate (at least 80%)

Secondary

Measure	Time frame	Description
SF-12 quality of life	From enrollment to the end of wordshop at 6 months	The secondary outcome measure will be measured by the SF-12 quality of life, before and after the 5 workshops. The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life.

Countries

France

Contacts

CONTACTMarie BARAIS, MD

marie.barais@gmail.com+332 98 01 64 02

CONTACTTiphaine MENEZ

tiphaine.menez@chu-brest.fr+33230338460

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026